Phreesia (PHR) Aperçu de l'action
Phreesia, Inc. fournit un logiciel intégré basé sur SaaS et une plateforme de paiement pour le secteur de la santé aux États-Unis et au Canada. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 2/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
PHR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Phreesia, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$8.78 |
| Plus haut sur 52 semaines | US$32.76 |
| Plus bas sur 52 semaines | US$7.77 |
| Bêta | 0.89 |
| Variation sur 1 mois | -6.20% |
| Variation sur 3 mois | -30.92% |
| Variation sur 1 an | -63.93% |
| Variation sur 3 ans | -70.64% |
| Variation sur 5 ans | -82.16% |
| Évolution depuis l'introduction en bourse | -64.99% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.Mise à jour du récit • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.Mise à jour du récit • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Recent updates
Mise à jour du récit • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.Mise à jour du récit • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.Mise à jour du récit • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Seeking Alpha • Apr 07
Phreesia: Market Delivers A Resounding Vote Of No Confidence (Rating Downgrade)
Summary Phreesia is downgraded from buy to hold after plunging to all-time lows post-Q4 2026, driven by reduced revenue guidance and significant market headwinds. PHR cut FY2027 revenue guidance by 6.7% at the midpoint and now expects only low single-digit revenue per AHSC growth, signaling stalling momentum post-AccessOne acquisition. Despite record free cash flow and maintained adjusted EBITDA guidance, margin protection claims lack specificity amid rising stock-based compensation and upcoming AccessOne investments. Valuation is at 1.0x sales TTM, but with growth stalled and market confidence lost, PHR is now a 'prove it' stock before any upgrade consideration. Read the full article on Seeking AlphaMise à jour du récit • Mar 26
PHR: Profitability Focus And Intake Reach Will Support Future Multiple Resilience
Analyst price targets on Phreesia have been trimmed by a few dollars to around the mid $20s, as analysts factor in slightly lower revenue growth and profit margin assumptions while still using a relatively high future P/E of about 37x. Analyst Commentary Recent Street research on Phreesia has centered on fine tuning price targets and reassessing how much investors should pay for the company’s earnings profile, rather than making wholesale shifts in views on the business itself.Mise à jour du récit • Mar 11
PHR: Profitability Pivot And Intake Network Breadth Will Support Future Margin Expansion
Analysts have trimmed their average price targets on Phreesia by roughly $5 to the mid $20s, reflecting a mix of caution after a challenging period for health tech stocks and continued confidence in the company’s profitability pivot and patient intake platform. Analyst Commentary Recent Street research on Phreesia clusters around a common theme, lower price targets but generally constructive views on the company’s execution and path to profitability.Mise à jour du récit • Feb 24
PHR: Profitability Pivot And AccessOne Integration Will Drive Future Margin Expansion
The updated analyst price target for Phreesia reflects a modest trim of fair value to about $28.05, as analysts recalibrate their models following a series of target cuts to the $24 to $30 range. They continue to cite the company’s profitability pivot and patient intake platform scale as key parts of the long-term thesis.Mise à jour du récit • Feb 10
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts have nudged their price targets on Phreesia slightly lower, trimming fair value estimates by about $0.32 to reflect modestly updated assumptions on discount rates, margins, and future P/E. At the same time, recent research highlights both reduced targets in health tech and continued optimism around the company’s patient intake and payments platform.Mise à jour du récit • Jan 26
PHR: Profitability Pivot And AccessOne Synergies Will Support Future EBITDA Improvement
Analysts have nudged their fair value estimate for Phreesia slightly lower to about $28.63 per share, reflecting modestly softer assumptions for revenue growth, profit margins, and future P/E multiples following a series of recent price target cuts and fresh coverage initiations. Analyst Commentary Recent research paints a mixed picture for Phreesia, with several firms trimming price targets while others initiate or resume positive ratings.Mise à jour du récit • Jan 12
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts trimmed their fair value estimate for Phreesia to about $29.16 from $29.82 and lowered future P/E assumptions, pointing to reduced Street price targets in the mid $20s, even as research notes highlight the company’s profitability focus, margin progress, and reach across U.S. patient visits. Analyst Commentary Street research on Phreesia is mixed, with several firms trimming price targets while still highlighting profitability efforts, margin progress, and the scale of the platform across U.S. patient visits.Mise à jour du récit • Dec 24
PHR: Cross Sell And AccessOne Integration Will Drive Future EBITDA Expansion
Narrative Update Analysts have modestly trimmed their price target on Phreesia to approximately $29.82 from about $32.12 per share, reflecting slightly lower assumptions for revenue growth and profit margins even as they highlight the company’s growing cross-sell traction, long-term lift from the pending AccessOne acquisition, and potential for significant operating leverage to drive EBITDA growth in the high-20s to low-30s percentage range. Analyst Commentary Analysts generally view Phreesia positively, with recent coverage initiating the stock with an Outperform rating and a price target modestly above current levels, citing a strengthening growth and profitability profile.Mise à jour du récit • Dec 10
PHR: Cross Selling Momentum Will Drive Stronger Long Term EBITDA Expansion
Analysts have modestly reduced their price target on Phreesia from $33.73 to $32.12 per share, citing expectations for stronger long term EBITDA growth supported by cross selling traction and operating leverage, as well as incremental upside from the pending AccessOne acquisition. Analyst Commentary Analysts highlight that Phreesia's current valuation reflects confidence in its ability to execute on growth initiatives while expanding margins, but they also caution that the shares already price in a meaningful portion of the long term opportunity.Article d’analyse • Sep 27
Phreesia, Inc.'s (NYSE:PHR) 26% Cheaper Price Remains In Tune With Revenues
Phreesia, Inc. ( NYSE:PHR ) shareholders won't be pleased to see that the share price has had a very rough month...Mise à jour du récit • Sep 06
AI Integration And Digital Adoption Will Expand Healthcare Services
Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.Nouveau récit • May 27
Digital Healthcare Tools Will Expand Market Reach
Expanding digital adoption and data-driven solutions are driving operational efficiency, deeper client relationships, and long-term recurring revenue growth.Article d’analyse • Apr 29
Revenues Tell The Story For Phreesia, Inc. (NYSE:PHR)
There wouldn't be many who think Phreesia, Inc.'s ( NYSE:PHR ) price-to-sales (or "P/S") ratio of 3.4x is worth a...Article d’analyse • Mar 07
Why Phreesia, Inc. (NYSE:PHR) Could Be Worth Watching
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Article d’analyse • Feb 14
Phreesia (NYSE:PHR) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Dec 27
Phreesia, Inc.'s (NYSE:PHR) Shares Climb 27% But Its Business Is Yet to Catch Up
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Dec 12
Phreesia Has Turned The Corner, Can It Continue To Mend?
Summary Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, while fiscal 2026 projects slower revenue growth but significant EBITDA improvement. Strong cash flow and disciplined expense management are encouraging, with the company maintaining positive cash flows and holding $82M in cash. Despite current trading challenges, Phreesia’s innovative healthcare solutions and partnerships position it well for future growth and potential valuation recovery. Read the full article on Seeking AlphaArticle d’analyse • Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
With a price-to-sales (or "P/S") ratio of 3.1x Phreesia, Inc. ( NYSE:PHR ) may be sending bearish signals at the...Article d’analyse • Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Phreesia, Inc. ( NYSE:PHR ) last week reported its latest second-quarter results, which makes it a good time for...Seeking Alpha • Sep 05
Phreesia: Remain Bullish Given The Healthy Growth Outlook
Summary I maintain a buy rating for PHR, driven by strong client growth, solid revenue outlook, and increasing transaction sizes in the pipeline. PHR's 2Q25 results show 19% y/y revenue growth and improved profitability, with positive EBITDA and FCF, indicating strong financial health. Despite a slight decline in revenue per AHSC, larger client acquisitions and increased transaction sizes support my 20% growth expectation. Read the full article on Seeking AlphaArticle d’analyse • Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jun 06
Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Summary Phreesia's revenue grew 20.7% year-over-year, with subscription revenue growing 23.4% and payment processing revenue growing 11.6%. The company added 103 new clients in the quarter, beating guidance, and expects to add around 100 more in the next quarter. Phreesia's focus on profitability is showing positive results, with EBITDA margin expanding and guidance suggesting further improvement. Read the full article on Seeking AlphaArticle d’analyse • May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Article d’analyse • May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Phreesia fair value estimate is US$36.24 Current share price...Article d’analyse • Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it received a lot of attention from a substantial...Seeking Alpha • Apr 03
Phreesia Continues To Stay Positive On The Business Growth
Summary Phreesia is expected to continue growing revenue at a rate of 20%+ and see an increase in adjusted EBITDA margin as the business scales. PHR has shown strong customer additions, driving revenue growth, and has added new products to contribute to revenue growth. Management has raised profitability guidance for FY25, which is expected to drive positive stock sentiment. Read the full article on Seeking AlphaRendement pour les actionnaires
| PHR | US Healthcare Services | US Marché | |
|---|---|---|---|
| 7D | 0.1% | 1.1% | -0.3% |
| 1Y | -63.9% | -38.1% | 26.7% |
Rendement vs Industrie: PHR a sous-performé le secteur US Healthcare Services qui a rapporté -38.1 % au cours de l'année écoulée.
Rendement vs marché: PHR a sous-performé le marché US qui a rapporté 26.7 % au cours de l'année écoulée.
Volatilité des prix
| PHR volatility | |
|---|---|
| PHR Average Weekly Movement | 10.8% |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: PHR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PHR ( 11% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2005 | 1,789 | Chaim Indig | www.phreesia.com |
Phreesia, Inc. fournit un logiciel intégré basé sur le SaaS et une plateforme de paiement pour le secteur de la santé aux États-Unis et au Canada. Elle offre des solutions comprenant l'optimisation des rendez-vous et la gestion des références à l'aide de flux de travail basés sur l'IA ; une solution de réponse intelligente basée sur l'IA ; des communications avec les patients soutenues par des solutions vocales et de messagerie ; des solutions de paiement intégrées dans les flux de travail d'accueil et de post-visite, et des solutions de financement qui permettent aux organisations de soins de santé d'accélérer les encaissements tout en offrant des options de paiement flexibles aux patients ; et l'accueil numérique et la capture de données cliniques, des outils d'engagement et d'activation des patients, ainsi que des solutions de mesure et d'analyse. Elle propose également des PhreesiaPads, des tablettes d'admission en libre-service, et des kiosques d'arrivée, qui sont des kiosques sur place.
Phreesia, Inc. Résumé des fondamentaux
| PHR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$537.75m |
| Bénéfices(TTM) | US$2.31m |
| Recettes(TTM) | US$480.59m |
231.4x
Ratio P/E1.1x
Ratio P/SLe site PHR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PHR compte de résultat (TTM) | |
|---|---|
| Recettes | US$480.59m |
| Coût des recettes | US$154.12m |
| Marge brute | US$326.47m |
| Autres dépenses | US$324.16m |
| Les revenus | US$2.31m |
Derniers bénéfices déclarés
Jan 31, 2026
Prochaine date de publication des résultats
May 27, 2026
| Résultat par action (EPS) | 0.038 |
| Marge brute | 67.93% |
| Marge bénéficiaire nette | 0.48% |
| Ratio dettes/capitaux propres | 27.5% |
Quelles ont été les performances à long terme de PHR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 22:27 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/01/31 |
| Revenus annuels | 2026/01/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Phreesia, Inc. est couverte par 23 analystes. 19 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Glen Santangelo | Barclays |
| Zhilin Long | Berenberg |